Timing of cesarean delivery for fetal heart rate abnormalities in hypertensive pregnancies induced with oral misoprostol or Foley catheter: Secondary analysis of a randomized clinical trial

被引:0
|
作者
Londero, Ambrogio P. [1 ,2 ,5 ]
Fichera, Anna [3 ]
Orabona, Rossana [3 ]
Cagnacci, Angelo [2 ,4 ]
Prefumo, Federico [1 ]
机构
[1] IRCCS Ist Giannina Gaslini, Obstet & Gynecol Unit, Genoa, Italy
[2] Univ Genoa, Dept Neurol Rehabil Ophthalmol Genet Maternal & In, Genoa, Italy
[3] Univ Brescia, Dept Clin & Expt Sci, Brescia, Italy
[4] IRCCS Osped Policlin San Martino, Acad Unit Obstet & Gynecol, Genoa, Italy
[5] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Largo Rosanna Benzi 10, I-16132 Genoa, Italy
关键词
CD; cesarean delivery; fetal heart rate; FHR anomalies; Foley catheter; labor induction; misoprostol; uterine hyperstimulation; NEONATAL OUTCOMES; INDUCTION; INFORM; INDIA; WOMEN; LABOR;
D O I
10.1002/ijgo.15375
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveThe study aims to assess how oral misoprostol for cervical ripening affects the time of cesarean delivery (CD) for fetal heart rate (FHR) abnormalities in pre-eclampsia patients. Secondary goals include determining the role of uterine hyperstimulation, comparing misoprostol with Foley catheter, and identifying risk factors for FHR abnormalities associated with CD.MethodsA previously published randomized clinical trial was subjected to a secondary analysis (NCT01801410). We conducted a time-dependent analysis, stratifying the population based on the final mode of induction used (low-dose oral misoprostol vs Foley catheter).ResultsThere was no CD for FHR abnormalities within 2 h of starting misoprostol. At 5 h, the cumulative incidence of CD for FHR abnormalities in the misoprostol group was 2.10%, while it was 1.00% in the Foley group (P = 0.565). After 25 h, the CD risk for FHR abnormalities remained constant in both groups at 21.00% (95% confidence interval [CI] 15.00%-28.00%). Within 5 h of misoprostol induction, the risk of uterine hyperstimulation was similar in both groups (0.33% in misoprostol vs 0.34% in Foley group, P = 0.161). The risk of CD for FHR abnormalities was unaffected by newborn weight centiles.ConclusionThere was no significant difference in CD risk for FHR abnormalities between misoprostol and Foley catheter induction. Nonetheless, the cumulative incidence of CD for FHR abnormalities increased faster in the misoprostol group, indicating that FHR monitoring timing should be tailored to the induction method. The incidence of cesarean delivery for fetal heart anomalies increased faster in the misoprostol group than in Foley group, and for that reason tailoring fetal monitoring timing to induction method is critical.
引用
收藏
页码:373 / 380
页数:8
相关论文
共 7 条
  • [1] Cesarean delivery for intrapartum fetal heart rate abnormalities: Incorporating survey data into clinical judgement
    Skupski, DW
    Chervenak, FA
    McCullough, LB
    Horowitz, S
    [J]. OBSTETRICS AND GYNECOLOGY, 1996, 88 (01): : 60 - 64
  • [2] Foley catheter vs. oral misoprostol to induce labour among hypertensive women in India: a cost-consequence analysis alongside a clinical trial
    Leigh, S.
    Granby, P.
    Haycox, A.
    Mundle, S.
    Bracken, H.
    Khedikar, V.
    Mulik, J.
    Faragher, B.
    Easterling, T.
    Turner, M. A.
    Alfirevic, Z.
    Winikoff, B.
    Weeks, A. D.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2018, 125 (13) : 1734 - 1742
  • [3] Oral misoprostol for 48 hours versus a supra cervical foley catheter for 48 hours for induction of labour in post dated pregnancies: a randomized control trial
    Amarasena, Buddhika
    Goonewardene, Malik
    Perera, Rashanthie
    Furukan, Rameez
    [J]. CEYLON MEDICAL JOURNAL, 2021, 66 (02) : 77 - 86
  • [4] Fetal ECG analysis of the ST segment as an adjunct to intrapartum fetal heart rate monitoring: a randomized clinical trial
    Saade, George
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2015, 212 (01) : S2 - S2
  • [5] Tranexamic acid for the prevention of blood loss after cesarean among women with twins: a secondary analysis of the TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery randomized clinical trial
    Sentilhes, Loic
    Madar, Hugo
    Le Lous, Maela
    Senat, Marie Victoire
    Winer, Norbert
    Rozenberg, Patrick
    Kayem, Gilles
    Verspyck, Eric
    Fuchs, Florent
    Azria, Elie
    Gallot, Denis
    Korb, Diane
    Desbriere, Raoul
    Le Ray, Camille
    Chauleur, Celine
    de Marcillac, Fanny
    Perrotin, Franck
    Parant, Olivier
    Salomon, Laurent J.
    Gauchotte, Emilie
    Bretelle, Florence
    Sananes, Nicolas
    Bohec, Caroline
    Mottet, Nicolas
    Legendre, Guillaume
    Letouzey, Vincent
    Haddad, Bassam
    Vardon, Delphine
    Mattuizzi, Aurelien
    Froeliger, Alizee
    Bouchghoul, Hanane
    Daniel, Valerie
    Regueme, Sophie
    Roussillon, Caroline
    Georget, Aurore
    Darsonval, Astrid
    Benard, Antoine
    Deneux-Tharaux, Catherine
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2022, 227 (06) : 889.e1 - 889.e17
  • [6] Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial
    Mc Causland, Finnian R.
    Claggett, Brian L.
    Vaduganathan, Muthiah
    Desai, Akshay
    Jhund, Pardeep
    Vardeny, Orly
    Fang, James C.
    de Boer, Rudolf A.
    Docherty, Kieran F.
    Hernandez, Adrian F.
    Inzucchi, Silvio E.
    Kosiborod, Mikhail N.
    Lam, Carolyn S. P.
    Martinez, Felipe
    Saraiva, Jose F. Kerr
    Mcgrath, Martina M.
    Shah, Sanjiv J.
    Verma, Subodh
    Langkilde, Anna Maria
    Petersson, Magnus
    Mcmurray, John J. V.
    Solomon, Scott D.
    [J]. JAMA CARDIOLOGY, 2024, 9 (02) : 144 - 152
  • [7] Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial (vol 9, pg 144, 2024)
    Magnani, Jared W.
    Allen, Norrina B.
    [J]. JAMA CARDIOLOGY, 2024, 9 (07) : 674 - 674